Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Phenotype-independent DNA methylation changes in prostate cancer.

Pellacani D, Droop AP, Frame FM, Simms MS, Mann VM, Collins AT, Eaves CJ, Maitland NJ.

Br J Cancer. 2018 Oct;119(9):1133-1143. doi: 10.1038/s41416-018-0236-1. Epub 2018 Oct 15.

PMID:
30318509
2.

Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.

Noble AR, Maitland NJ, Berney DM, Rumsby MG.

Br J Cancer. 2018 Jan;118(2):189-199. doi: 10.1038/bjc.2017.391. Epub 2017 Nov 14.

3.

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer.

Butler DE, Marlein C, Walker HF, Frame FM, Mann VM, Simms MS, Davies BR, Collins AT, Maitland NJ.

Oncotarget. 2017 May 23;8(34):56698-56713. doi: 10.18632/oncotarget.18082. eCollection 2017 Aug 22.

4.

Can Decellularised Prostate Tissue Be Used to Model Tumour Malignancy?

Maitland NJ.

Eur Urol Focus. 2016 Oct;2(4):409-411. doi: 10.1016/j.euf.2016.05.001. Epub 2016 May 18.

PMID:
28723473
5.

The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling.

Nappo G, Handle F, Santer FR, McNeill RV, Seed RI, Collins AT, Morrone G, Culig Z, Maitland NJ, Erb HHH.

Oncogenesis. 2017 May 29;6(5):e342. doi: 10.1038/oncsis.2017.23.

6.

A Detailed Analysis of Gene Expression in Human Basal, Luminal, and Stromal Cell Populations from Benign Prostatic Hyperplasia Tissues and Comparisons with Cultured Basal Cells.

Rane JK, Droop AP, Maitland NJ.

Eur Urol. 2017 Jul;72(1):157-159. doi: 10.1016/j.eururo.2017.03.024. Epub 2017 Apr 3. No abstract available.

7.

Re: The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.

Maitland NJ.

Eur Urol. 2017 Feb;71(2):302-303. doi: 10.1016/j.eururo.2016.08.062. Epub 2016 Sep 13. No abstract available.

8.

Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers.

Rane JK, Erb HH, Nappo G, Mann VM, Simms MS, Collins AT, Visakorpi T, Maitland NJ.

Oncotarget. 2016 Aug 9;7(32):51965-51980. doi: 10.18632/oncotarget.10207.

9.

Harvesting Human Prostate Tissue Material and Culturing Primary Prostate Epithelial Cells.

Frame FM, Pellacani D, Collins AT, Maitland NJ.

Methods Mol Biol. 2016;1443:181-201. doi: 10.1007/978-1-4939-3724-0_12.

PMID:
27246341
10.

Stem cells and the role of ETS transcription factors in the differentiation hierarchy of normal and malignant prostate epithelium.

Archer LK, Frame FM, Maitland NJ.

J Steroid Biochem Mol Biol. 2017 Feb;166:68-83. doi: 10.1016/j.jsbmb.2016.05.006. Epub 2016 May 14. Review.

PMID:
27185499
11.

An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells.

Peitzsch C, Cojoc M, Hein L, Kurth I, Mäbert K, Trautmann F, Klink B, Schröck E, Wirth MP, Krause M, Stakhovsky EA, Telegeev GD, Novotny V, Toma M, Muders M, Baretton GB, Frame FM, Maitland NJ, Baumann M, Dubrovska A.

Cancer Res. 2016 May 1;76(9):2637-51. doi: 10.1158/0008-5472.CAN-15-2116. Epub 2016 Mar 16.

12.

The molecular and cellular origin of human prostate cancer.

Packer JR, Maitland NJ.

Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1238-60. doi: 10.1016/j.bbamcr.2016.02.016. Epub 2016 Feb 26. Review.

13.

Cyclin A1 and P450 Aromatase Promote Metastatic Homing and Growth of Stem-like Prostate Cancer Cells in the Bone Marrow.

Miftakhova R, Hedblom A, Semenas J, Robinson B, Simoulis A, Malm J, Rizvanov A, Heery DM, Mongan NP, Maitland NJ, Allegrucci C, Persson JL.

Cancer Res. 2016 Apr 15;76(8):2453-64. doi: 10.1158/0008-5472.CAN-15-2340. Epub 2016 Feb 26.

14.

Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future.

Hirst AM, Frame FM, Arya M, Maitland NJ, O'Connell D.

Tumour Biol. 2016 Jun;37(6):7021-31. doi: 10.1007/s13277-016-4911-7. Epub 2016 Feb 18. Review.

15.

Mechanisms of growth inhibition of primary prostate epithelial cells following gamma irradiation or photodynamic therapy include senescence, necrosis, and autophagy, but not apoptosis.

Frame FM, Savoie H, Bryden F, Giuntini F, Mann VM, Simms MS, Boyle RW, Maitland NJ.

Cancer Med. 2016 Jan;5(1):61-73. doi: 10.1002/cam4.553. Epub 2015 Nov 21.

16.

Telomerase Activity and Telomere Length in Human Benign Prostatic Hyperplasia Stem-like Cells and Their Progeny Implies the Existence of Distinct Basal and Luminal Cell Lineages.

Rane JK, Greener S, Frame FM, Mann VM, Simms MS, Collins AT, Berney DM, Maitland NJ.

Eur Urol. 2016 Apr;69(4):551-554. doi: 10.1016/j.eururo.2015.09.039. Epub 2015 Oct 9.

PMID:
26455356
17.

Construction of therapeutically relevant human prostate epithelial fate map by utilising miRNA and mRNA microarray expression data.

Rane JK, Ylipää A, Adamson R, Mann VM, Simms MS, Collins AT, Visakorpi T, Nykter M, Maitland NJ.

Br J Cancer. 2015 Aug 11;113(4):611-5. doi: 10.1038/bjc.2015.262. Epub 2015 Jul 23.

18.

CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.

Khanna A, Rane JK, Kivinummi KK, Urbanucci A, Helenius MA, Tolonen TT, Saramäki OR, Latonen L, Manni V, Pimanda JE, Maitland NJ, Westermarck J, Visakorpi T.

Oncotarget. 2015 Aug 14;6(23):19661-70.

19.

miR-25 Modulates Invasiveness and Dissemination of Human Prostate Cancer Cells via Regulation of αv- and α6-Integrin Expression.

Zoni E, van der Horst G, van de Merbel AF, Chen L, Rane JK, Pelger RC, Collins AT, Visakorpi T, Snaar-Jagalska BE, Maitland NJ, van der Pluijm G.

Cancer Res. 2015 Jun 1;75(11):2326-36. doi: 10.1158/0008-5472.CAN-14-2155. Epub 2015 Apr 9.

20.

Low-temperature plasma treatment induces DNA damage leading to necrotic cell death in primary prostate epithelial cells.

Hirst AM, Simms MS, Mann VM, Maitland NJ, O'Connell D, Frame FM.

Br J Cancer. 2015 Apr 28;112(9):1536-45. doi: 10.1038/bjc.2015.113. Epub 2015 Apr 2.

21.

Differential regulation of TROP2 release by PKC isoforms through vesicles and ADAM17.

Wanger TM, Dewitt S, Collins A, Maitland NJ, Poghosyan Z, Knäuper V.

Cell Signal. 2015 Jul;27(7):1325-35. doi: 10.1016/j.cellsig.2015.03.017. Epub 2015 Mar 26.

PMID:
25817572
22.

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.

Santer FR, Erb HH, Oh SJ, Handle F, Feiersinger GE, Luef B, Bu H, Schäfer G, Ploner C, Egger M, Rane JK, Maitland NJ, Klocker H, Eder IE, Culig Z.

Oncotarget. 2015 Mar 20;6(8):6105-22.

23.

Carcinoma-derived exosomes modify microenvironment.

Maitland NJ.

Oncotarget. 2015 Jan 30;6(3):1344-5.

24.

MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets.

Rane JK, Scaravilli M, Ylipää A, Pellacani D, Mann VM, Simms MS, Nykter M, Collins AT, Visakorpi T, Maitland NJ.

Eur Urol. 2015 Jan;67(1):7-10. doi: 10.1016/j.eururo.2014.09.005. Epub 2014 Sep 16.

PMID:
25234358
25.

Low Temperature Plasma Causes Double-Strand Break DNA Damage in Primary Epithelial Cells Cultured from a Human Prostate Tumour.

Hirst AM, Frame FM, Maitland NJ, O'Connell D.

IEEE Trans Plasma Sci IEEE Nucl Plasma Sci Soc. 2014 Sep 9;42(10):2740-2741.

26.

Phorbol ester stimulates ethanolamine release from the metastatic basal prostate cancer cell line PC3 but not from prostate epithelial cell lines LNCaP and P4E6.

Schmitt J, Noble A, Otsuka M, Berry P, Maitland NJ, Rumsby MG.

Br J Cancer. 2014 Oct 14;111(8):1646-56. doi: 10.1038/bjc.2014.457. Epub 2014 Aug 19.

27.

Low temperature plasma: a novel focal therapy for localized prostate cancer?

Hirst AM, Frame FM, Maitland NJ, O'Connell D.

Biomed Res Int. 2014;2014:878319. doi: 10.1155/2014/878319. Epub 2014 Mar 13. Review.

28.

Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer.

Schenk E, Essand M, Kraaij R, Adamson R, Maitland NJ, Bangma CH.

Hum Gene Ther Clin Dev. 2014 Mar;25(1):7-15. doi: 10.1089/humc.2013.181.

PMID:
24649837
30.

Conserved two-step regulatory mechanism of human epithelial differentiation.

Rane JK, Droop AP, Pellacani D, Polson ES, Simms MS, Collins AT, Caves LS, Maitland NJ.

Stem Cell Reports. 2014 Feb 6;2(2):180-8. doi: 10.1016/j.stemcr.2014.01.001. eCollection 2014 Feb 11.

31.

DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation.

Pellacani D, Kestoras D, Droop AP, Frame FM, Berry PA, Lawrence MG, Stower MJ, Simms MS, Mann VM, Collins AT, Risbridger GP, Maitland NJ.

Cell Death Differ. 2014 May;21(5):761-73. doi: 10.1038/cdd.2013.202. Epub 2014 Jan 24.

32.

HDAC inhibitor confers radiosensitivity to prostate stem-like cells.

Frame FM, Pellacani D, Collins AT, Simms MS, Mann VM, Jones GD, Meuth M, Bristow RG, Maitland NJ.

Br J Cancer. 2013 Dec 10;109(12):3023-33. doi: 10.1038/bjc.2013.691. Epub 2013 Nov 12.

33.

Words of wisdom: re: prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.

Maitland NJ.

Eur Urol. 2013 Aug;64(2):341-2. doi: 10.1016/j.eururo.2013.05.014. No abstract available.

PMID:
23830230
34.

JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells.

Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, Bhasin D, Chettiar S, Li C, Li PK, Maitland NJ, Collins AT.

Cancer Res. 2013 Aug 15;73(16):5288-98. doi: 10.1158/0008-5472.CAN-13-0874. Epub 2013 Jul 3.

35.

Evaluating baculovirus as a vector for human prostate cancer gene therapy.

Swift SL, Rivera GC, Dussupt V, Leadley RM, Hudson LC, Ma de Ridder C, Kraaij R, Burns JE, Maitland NJ, Georgopoulos LJ.

PLoS One. 2013 Jun 6;8(6):e65557. doi: 10.1371/journal.pone.0065557. Print 2013.

36.

A fusion at the root of prostate cancer.

Maitland NJ.

Asian J Androl. 2013 Sep;15(5):592-3. doi: 10.1038/aja.2013.75. Epub 2013 Jun 10. No abstract available.

37.

Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells.

Ulukaya E, Frame FM, Cevatemre B, Pellacani D, Walker H, Mann VM, Simms MS, Stower MJ, Yilmaz VT, Maitland NJ.

PLoS One. 2013 May 10;8(5):e64278. doi: 10.1371/journal.pone.0064278. Print 2013.

38.

Retinoic acid represses invasion and stem cell phenotype by induction of the metastasis suppressors RARRES1 and LXN.

Oldridge EE, Walker HF, Stower MJ, Simms MS, Mann VM, Collins AT, Pellacani D, Maitland NJ.

Oncogenesis. 2013 Apr 15;2:e45. doi: 10.1038/oncsis.2013.6.

39.

A preclinical xenograft model of prostate cancer using human tumors.

Lawrence MG, Taylor RA, Toivanen R, Pedersen J, Norden S, Pook DW, Frydenberg M; Australian Prostate Cancer BioResource, Papargiris MM, Niranjan B, Richards MG, Wang H, Collins AT, Maitland NJ, Risbridger GP.

Nat Protoc. 2013 May;8(5):836-48. doi: 10.1038/nprot.2013.043. Epub 2013 Apr 4.

PMID:
23558784
40.

Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells.

Polson ES, Lewis JL, Celik H, Mann VM, Stower MJ, Simms MS, Rodrigues G, Collins AT, Maitland NJ.

Nat Commun. 2013;4:1623. doi: 10.1038/ncomms2627.

PMID:
23535644
41.

Prominin-1 (CD133) Expression in the Prostate and Prostate Cancer: A Marker for Quiescent Stem Cells.

Pellacani D, Oldridge EE, Collins AT, Maitland NJ.

Adv Exp Med Biol. 2013;777:167-84. doi: 10.1007/978-1-4614-5894-4_11. Review.

PMID:
23161082
42.

Advanced prostate cancer--a case for adjuvant differentiation therapy.

Rane JK, Pellacani D, Maitland NJ.

Nat Rev Urol. 2012 Oct;9(10):595-602. doi: 10.1038/nrurol.2012.157. Epub 2012 Aug 14. Review.

PMID:
22890299
43.

Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status.

Taylor RA, Toivanen R, Frydenberg M, Pedersen J, Harewood L; Australian Prostate Cancer Bioresource, Collins AT, Maitland NJ, Risbridger GP.

Stem Cells. 2012 Jun;30(6):1087-96. doi: 10.1002/stem.1094. Erratum in: Stem Cells. 2012 Aug;30(8):1786.

44.

Retinoic acid and androgen receptors combine to achieve tissue specific control of human prostatic transglutaminase expression: a novel regulatory network with broader significance.

Rivera-Gonzalez GC, Droop AP, Rippon HJ, Tiemann K, Pellacani D, Georgopoulos LJ, Maitland NJ.

Nucleic Acids Res. 2012 Jun;40(11):4825-40. doi: 10.1093/nar/gks143. Epub 2012 Feb 22.

45.

Cancer stem cells, models of study and implications of therapy resistance mechanisms.

Frame FM, Maitland NJ.

Adv Exp Med Biol. 2011;720:105-18. doi: 10.1007/978-1-4614-0254-1_9. Review.

PMID:
21901622
46.

A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer.

Magnusson MK, Kraaij R, Leadley RM, De Ridder CM, van Weerden WM, Van Schie KA, Van der Kroeg M, Hoeben RC, Maitland NJ, Lindholm L.

Hum Gene Ther. 2012 Jan;23(1):70-82. doi: 10.1089/hum.2011.016. Epub 2011 Oct 12.

47.

In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus.

Adamson RE, Frazier AA, Evans H, Chambers KF, Schenk E, Essand M, Birnie R, Mitry RR, Dhawan A, Maitland NJ.

Hum Gene Ther. 2012 Feb;23(2):218-30. doi: 10.1089/hum.2011.021. Epub 2011 Sep 9.

PMID:
21823897
48.

Baculoviruses as gene therapy vectors for human prostate cancer.

Rivera-Gonzalez GC, Swift SL, Dussupt V, Georgopoulos LJ, Maitland NJ.

J Invertebr Pathol. 2011 Jul;107 Suppl:S59-70. doi: 10.1016/j.jip.2011.05.006. Review.

PMID:
21784232
49.

Prostate cancer stem cells: are they androgen-responsive?

Oldridge EE, Pellacani D, Collins AT, Maitland NJ.

Mol Cell Endocrinol. 2012 Sep 5;360(1-2):14-24. doi: 10.1016/j.mce.2011.07.008. Epub 2011 Jul 23. Review.

PMID:
21802490
50.

Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer.

Pellacani D, Packer RJ, Frame FM, Oldridge EE, Berry PA, Labarthe MC, Stower MJ, Simms MS, Collins AT, Maitland NJ.

Mol Cancer. 2011 Jul 29;10:94. doi: 10.1186/1476-4598-10-94.

Supplemental Content

Loading ...
Support Center